Impel Pharmaceuticals

United States
Seattle, Washington, United States, 98122

Company profile

Impel Pharmaceuticals company profile

Impel Pharmaceuticals is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA™ for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Business identity

Contact email
[email protected]
Phone number
2067261217
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2008-01-01, Year

Headquarters

Postal code
98122
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
13
Total equity funding
$151.9M
Last funding
Post IPO Debt / $50M / 2022-03-17
Last equity funding
Post IPO Equity / $45M
Investors
10
Lead investors
7
Founders
3
Articles
58
Exited on
2021-04-22

Founders and investors

Founders

John HoekmanMichael HiteRodney Ho

Lead investors

3M New VenturesAlliance of AngelsKohlberg Kravis Roberts & Co.NorwestOaktree Capital ManagementOxford Finance LLCSilicon Valley Bank

Investors

5AM VenturesKohlberg Kravis Roberts & Co.NorwestOaktree Capital ManagementVivo Capital